As a rule of thumb, the only items that clearly meet Teva’s threshold of materiality for disclosure are those involving M&A activity, management/BoD changes, litigation, or anything related to Copaxone. The change in status of a pending drug application falls short of the threshold, even for a product as important as generic Lovenox.
Market Data 
Markets 
AI
